Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jun;55(11):1459-1460.
doi: 10.1111/apt.16936.

Editorial: safety in numbers-cycling of biologics does not increase risk of adverse outcomes

Adam S Faye  1 , Jordan E Axelrad  1
Affiliations
Editorial

Editorial: safety in numbers-cycling of biologics does not increase risk of adverse outcomes

Adam S Faye et al. Aliment Pharmacol Ther. 2022 Jun.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. World J. Gastroenterol 2016;22:4794–4801. - PMC - PubMed
    1. Bonovas S, Fiorino G, Allocca M, et al. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clin. Gastroenterol. Hepatol 2016;14:1385–1397.e10. - PubMed
    1. Moens A, Sadat Seyed Tabib N, B V, et al. Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral centre. Aliment Pharmacol Ther. 2022; in press. - PubMed
    1. Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. Am. J. Gastroenterol 2014;109:163–169. - PubMed
    1. Waljee AK, Wiitala WL, Govani S, et al. Corticosteroid use and complications in a US inflammatory bowel disease cohort. PLoS ONE. 2016;11:e0158017. - PMC - PubMed

LinkOut - more resources